We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.
“We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with Pharma and Biotech companies like OliX,” said Alexandre Tokay, CEO of Vect-Horus.
“This partnership has the potential to accelerate the development of innovative treatments and bring renewed hope to patients worldwide, and we are looking forward to a strong collaboration with OliX.”